GlassScriptPhysician profile
Gregory J Gallina
NPI 1356437198
$647.50
in general payments reported to CMS, 2019-2025
13 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.40 · 2020: $31.94 · 2021: $10.46 · 2022: $38.09 · 2023: $79.31 · 2024: $86.49 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $219.22 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Thd America, INC. | $84.73 | 2022-2025 | |
| W. L. Gore & Associates, INC. | $53.14 | 2019 | |
| Braintree Laboratories, INC. | $50.45 | 2020-2025 | Sutab, Suflave |
| Ethicon US, LLC | $46.18 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $39.97 | 2019-2023 | Rebyota |
| Integra Lifesciences Corporation | $28.79 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Stryker Corporation | $27.66 | 2023 | Augment Injectable |
| Convatec INC. | $23.55 | 2023 | |
| Medtronic, INC. | $22.20 | 2024 | Interstim |
| Merck Sharp & Dohme LLC | $19.29 | 2024 | Dificid, Zinplava |
| Celltrion USA INC. | $18.96 | 2025 | Vegzelma |
| Abbvie INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Gallina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.